Tumor growth inhibitory effect of juglone and its radiation sensitizing potential: In vivo and in vitro studies

Integrative Cancer Therapies

Volumn 11, Issue 1, 2012, Pages 68-80

  Aithal, Kiran B ^a   Kumar, Sunil ^a   Rao, B Nageshwar ^a   Udupa, Nayanabhirama ^a   Rao, Satish Bola Sadashiva ^a  

^a MANIPAL UNIVERSITY   (India)

Author keywords

anticancer; DNA damage; juglone; melanoma; radiosensitization; reactive oxygen species

Indexed keywords

JUGLONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; COBALT THERAPY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DNA DAMAGE; FEMALE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NAPHTHOQUINONES; OXIDATIVE STRESS; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES;

EID: 79958800036     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411403477     Document Type: Article

References (53)

1. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004 ; 4: 737-747
2. Robinson MH. Radiotherapy: technical aspects. Medicine. 2008 ; 36: 9-14
3. Mans DR, da Rocha AB, Schwartsmann G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist. 2000 ; 5: 185-198
4. Li CJ, Li YZ, Pinto AV, Pardee AB. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA. 1999 ; 96: 13369-13374
5. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol. 2008 ; 128: 2575-2595
6. Horsman MR, Bohm L, Margison GP, et al. Tumor radiosensitizers-current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys. 2006 ; 64: 551-561
7. Pietras RJ, Weinberg OK. Antiangiogenic steroids in human cancer therapy. Evid Based Complement Alternat Med. 2005 ; 2: 49-57
8. Babula P, Adam V, Havel L, Kizek R. Naphthoquinones and their pharmacological properties [in Czech]. Ceska Slov Farm. 2007 ; 56: 114-120
9. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl- 1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006 ; 318: 484-494
10. Devi PU, Solomon FE, Sharada AC. Plumbagin, a plant naphthoquinone with antitumor and radiomodifying properties. Pharm Biol. 1999 ; 37: 231-236
11. Nair S, Nair RR, Srinivas P, Srinivas G, Pillai MR. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog. 2008 ; 47: 22-33
12. Prasad VS, Devi PU, Rao BS, Kamath R. Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro. Indian J Exp Biol. 1996 ; 34: 857-858
13. Bhatia K, Rahman S, Ali M, Raisuddin S. In vitro antioxidant activity of Juglans regia L. bark extract and its protective effect on cyclophosphamide- induced urotoxicity in mice. Redox Rep. 2006 ; 11: 273-279
14. Blumenthal M Walnut Hull, The Complete German Commission E Monographs. Austin, TX: American Botanical Council ; 1998 :
15. Duke JA, Ayensu ES Medicinal Plants of China. Algonac, MI: Reference Publications ; 1985 :
16. Oliveira I, Sousa A, Ferreira IC, Bento A, Estevinho L, Pereira JA. Total phenols, antioxidant potential and antimicrobial activity of walnut (Juglans regia L.) green husks. Food Chem Toxicol. 2008 ; 46: 2326-2331
17. Bhargava UC, Westfall BA. Antitumor activity of Juglans niga (black walnut) extractives. J Pharm Sci. 1968 ; 57: 1674-1677
18. Cenas N, Prast S, Nivinskas H, Sarlauskas J, Arner ES. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem. 2006 ; 281: 5593-5603
19. Ji YB, Qu ZY, Zou X. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol. 2011 ; 63: 69-78
20. Segura-Aguilar J, Jonsson K, Tidefelt U, Paul C. The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin- resistant human leukemia cells (HL-60). Leuk Res. 1992 ; 16: 631-637
21. Aithal BK, Kumar MR, Rao BN, Udupa N, Rao BS. Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells. Cell Biol Int. 2009 ; 33: 1039-1049
22. Ghosh MN Toxicity Studies. Fundamentals of Experimental Pharmacology. Kolkata, India: Scientific Book Agency ; 1984 :
23. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949 ; 96: 99-113
24. Devi PU, Kamath R, Rao BS. Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J Exp Biol. 2000 ; 38: 432-437
25. Olive PL, Durand RE, Raleigh JA, Luo C, Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer. 2000 ; 83: 1525-1531
26. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988 ; 175: 184-191
27. Puck TT, Marcus PI. A Rapid method for viable cell titration and clone production with Hela cells in tissue culture: the use of x-irradiated cells to supply conditioning factors. Proc Natl Acad Sci U S A. 1955 ; 41: 432-437
28. Kumar MR, Aithal K, Rao BN, Udupa N, Rao BS. Cytotoxic, genotoxic and oxidative stress induced by 1,4-naphthoquinone in B16F1 melanoma tumor cells. Toxicol In Vitro. 2009 ; 23: 242-250
29. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984 ; 22: 27-55
30. Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys. 2003 ; 57: 1075-1083
31. Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer. 2001 ; 34: S81 - S90
32. Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat. 2009 ; 19: 643-662
33. Brower V. Back to nature: extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst. 2008 ; 100: 838-839
34. Westfall BA, Russell RL, Auyong TK. Depressant agent from walnut hulls. Science. 1961 1617 ; 134 :
35. Boelkins JN, Everson LK, Auyong TK. Effects of intravenous juglone in the dog. Toxicon. 1968 ; 6: 99-102
36. Okada TA, Roberts E, Brodie AF. Mitotic abnormalities produced by juglone in Ehrlich ascites tumor cells. Proc Soc Exp Biol Med. 1967 ; 126: 583-588
37. Sugie S, Okamoto K, Rahman KM, et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett. 1998 ; 127: 177-183
38. Monks TJ, Walker SE, Flynn LM, Conti CJ, DiGiovanni J. Epidermal ornithine decarboxylase induction and mouse skin tumor promotion by quinones. Carcinogenesis. 1990 ; 11: 1795-1801
39. Van Duuren BL, Segal A, Tseng SS, et al. Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone). J Med Chem. 1978 ; 21: 26-31
40. Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death?. Clin Cancer Res. 2007 ; 13: 789-794
41. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009 ; 8: 579-591
42. Wondrak GT. NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med. 2007 ; 43: 178-190
43. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat. 2005 ; 8: 85-97
44. Fairbairn DW, Olive PL, O'Neill KL. The comet assay: a comprehensive review. Mutat Res. 1995 ; 339: 37-59
45. Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia. 1999 ; 1: 461-467
46. Kopjar N, Garaj-Vrhovac V, Milas I. Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay. Teratog Carcinog Mutagen. 2002 ; 22: 13-30
47. Mandala Rayabandla SK, Aithal K, Anandam A, et al. Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma. Drug Deliv. 2010 ; 17: 103-113
48. Devi PU, Akagi K, Ostapenko V, Tanaka Y, Sugahara T. Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera. Int J Radiat Biol. 1996 ; 69: 193-197
49. Chung HW, Wen J, Lim JB, Bang S, Park SW, Song SY. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. Int J Radiat Oncol Biol Phys. 2009 ; 75: 862-869
50. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol. 2007 ; 4: 86-100
51. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989 ; 49: 605-612
52. Murakami K, Haneda M, Iwata S, Yoshino M. Effect of hydroxy substituent on the prooxidant action of naphthoquinone compounds. Toxicol In Vitro. 2010 ; 24: 905-909
53. Ollinger K, Brunmark A. Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J Biol Chem. 1991 ; 266: 21496-21503